Antiatherogenic small, dense HDL—guardian angel of the arterial wall?

@article{Kontush2006AntiatherogenicSD,
  title={Antiatherogenic small, dense HDL—guardian angel of the arterial wall?},
  author={A. Kontush and M. Chapman},
  journal={Nature Clinical Practice Cardiovascular Medicine},
  year={2006},
  volume={3},
  pages={144-153}
}
Our understanding of the relationship between the atheroprotective activities of HDL and heterogeneity of HDL particles has advanced greatly. HDL particles are highly heterogeneous in structure, intravascular metabolism and antiatherogenic activity. In this review, we discuss new findings on the antiatherogenic properties of HDL particles. Small, dense HDL possesses potent antioxidative activity but this is compromised under conditions of atherogenic dyslipidemia. HDL functional deficiency… Expand
Functionality of HDL particles: Heterogeneity and relationships to cardiovascular disease
TLDR
This review summarizes current knowledge about the metabolism, structure and composition of HDL subpopulations isolated by different experimental approaches, focussing on multiple biological activities of HDL. Expand
Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention.
TLDR
Several evidences are showing that different pathologic conditions, especially those associated with an inflammatory response, can cause dramatic alterations of HDL protein and lipid cargo resulting in HDL dysfunction, and established and investigational drugs designed to affect lipid metabolism and to increase HDL-C are only partly effective in correcting HDL dysfunction. Expand
Effects of curcumin on HDL functionality
TLDR
It is concluded that curcumin may modulate markers of HDL function, such as apo‐AI, CETP, LCAT, PON1, MPO activities and levels, and improve HDL functionality, independent of HDL‐C levels. Expand
Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities
TLDR
Pharmacological normalization of HDL metabolism concomitantly with correction of circulating levels, composition and biological activities of HDL particles, with enrichment in apoA-I and reduction in HDL surface rigidity, may constitute an efficacious therapeutic approach to attenuate atherosclerosis in dyslipidaemic patients at high cardiovascular risk. Expand
Subfractions and subpopulations of HDL: an update.
TLDR
There is mounting evidence supporting HDL subclasses as an important biomarker to predict and/or reduce CV risk, and which subfractions are reliable markers of CV risk and/ or potential targets of novel, more focused, and effective therapies. Expand
The relationship between high density lipoprotein subclass profile and plasma lipids concentrations
  • L. Tian, M. Fu
  • Chemistry, Medicine
  • Lipids in Health and Disease
  • 2010
TLDR
The general shift toward smaller size of HDL particle size in HTG, HCL and MHL subjects, and the changes were more prominent with the elevation of TG and TC levels which imply that HDL maturation might be abnormal and RCT pathway might be weaken, suggest that plasma lipids, apos concentrations and apos ratios should be considered while assessing the CHD risk. Expand
Biological Consequences of Dysfunctional HDL.
TLDR
Analysis of pathological conditions leading to the formation of dysfunctional HDL and their role in atherosclerosis and beyond suggests pharmacological approaches aimed at restoring HDL functions may impact more significantly on CVD outcome than drugs used so far to increase HDL-C levels. Expand
Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity.
TLDR
It is concluded that in MetS, apoA-I-poor, small, dense HDL3c exert defective protection of endothelial cells from oxLDL-induced apoptosis, potentially reflecting functional anomalies intimately associated with abnormal neutral lipid core content. Expand
HDL Particle Size and Its Association with Paraoxonase-1 Activity in CAD Patients
TLDR
This case –control study revealed that CAD patients had a higher mean HDL particle size and lower concentrations of Apo-A1 and paraoxonase-1 activity, though the concentrations of HDL were significantly higher in cases due to statin therapy. Expand
Biological activities of HDL subpopulations and their relevance to cardiovascular disease.
TLDR
This review describes major HDL subpopulations and discusses new findings on the antiatherogenic properties of HDL particles, with the potential to reveal novel biomarkers of cardiovascular risk and new pharmacological targets. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
HDL metabolism in hypertriglyceridemic states: an overview.
TLDR
The evidence that triglyceride-enrichment of HDL is an important factor determining the rate at which HDL is catabolized is summarized, a mechanism which could explain, at least in part, the reduced plasma HDL cholesterol levels and particle number frequently observed in hypertriglyceridemic states. Expand
Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress
Objectives— The relationship of the structural and functional heterogeneity of HDL particles to protection of LDL against oxidative stress is indeterminate. Methods and Results— HDL subfractions ofExpand
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
In mediating the transfer of cholesteryl esters (CE) from antiatherogenic high density lipoprotein (HDL) to proatherogenic apolipoprotein (apo)-B-containing lipoprotein particles (including very lowExpand
A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity.
TLDR
Low HDL-C subjects display elevated oxidative stress and possess HDL particle subspecies with attenuated intrinsic antioxidative activity which is intimately related to their altered chemical composition. Expand
High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.
High density lipoprotein (HDL) cholesterol is an important risk factor for coronary heart disease, and HDL exerts various potentially antiatherogenic properties, including the mediation of reverseExpand
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions.
TLDR
Despite the large body of information identifying HDLs as potential therapeutic targets for the prevention of atherosclerosis, there remain many unanswered questions that must be addressed as a matter of urgency before embarking wholesale on HDL-C-raising therapies as strategies to prevent CHD. Expand
Therapeutic approaches to raising plasma HDL-cholesterol levels
TLDR
The clinical evidence in support of the pleiotropic effects of HDLs is reviewed, along with laboratory-based investigations of the molecular mechanisms of action, and three current strategies currently being considered to achieve this goal are reviewed. Expand
Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia
TLDR
Antioxidative activity of small dense HDL is deficient in type 2 diabetes, is intimately linked to oxidative stress, glycaemia and hypertriglyceridaemia and primarily reflects abnormal intrinsic physicochemical properties of HDL particles. Expand
Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.
TLDR
An increasing body of evidence suggests that several anti-inflammatory effects exerted by HDL can be attributed to the presence of lysosphingolipids in this lipoprotein fraction. Expand
Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.
TLDR
It is concluded that antioxidative activity of small, dense HDL subfractions of altered chemical composition is impaired in MetS and associated with elevated oxidative stress and insulin resistance and induction of selective increase in the circulating concentrations of dense HDLSubfractions may represent an innovative therapeutic approach for the attenuation of high cardiovascular risk inMetS. Expand
...
1
2
3
4
5
...